Skip to main content
Top
Published in: BMC Nephrology 1/2023

Open Access 01-12-2023 | Acute Kidney Injury | Case report

Cyclic neutropenia and concomitant IgA nephropathy: a case report

Authors: C. Kapogiannis, T. Zaggogianni, N. Stergiou, K. Kakleas, A. Kapogiannis, H. Gakiopoulou, C. Kanaka-Gantenbein

Published in: BMC Nephrology | Issue 1/2023

Login to get access

Abstract

Background

IgA nephropathy (IgAN) is universally recognized as one of the most common primary glomerular diseases in all ages. Cyclic neutropenia (CN) is a rare haematologic disorder that is associated with mutations of the ELANE gene. The co-occurrence of IgAN and CN is extremely rare. This is the first case report of a patient with IgAN and genetically confirmed CN.

Case presentation

We report a case of a 10-year-old boy who presented with recurrent viral upper respiratory tract infections accompanied by several episodes of febrile neutropenia, haematuria, proteinuria and acute kidney injury. Upon first admission, his physical examination was unremarkable. His kidney function was impaired, whereas his urine microscopy showed evidence of macroscopic haematuria and proteinuria. Further workup showed elevated IgA. The renal histology was consistent with mesangial and endocapillary hypercellularity with mild crescentic lesions, while immunofluorescence microscopy showed IgA-positive staining, which was characteristic of IgAN. Moreover, genetic testing confirmed the clinical diagnosis of CN, therefore Granulocyte colony-stimulating factor (G-CSF) was initiated to stabilize the neutrophil count. Regarding proteinuria control, the patient was initially treated with an Angiotensin-converting-enzyme inhibitor for approximately 28 months. However, due to progressive proteinuria (> 1 g/24 h), Corticosteroids (CS) were added for a period of 6 months according to the revised 2021 KDIGO guidelines with favorable outcome.

Conclusions

Patients with CN are more susceptible to recurrent viral infections, which can trigger IgAN attacks. In our case CS induced remarkable proteinuria remission. The use of G-CSF contributed to the resolution of severe neutropenic episodes, viral infections and concomitant AKI episodes, contributing to better prognosis of IgAN. Further studies are mandatory to determine whether there is a genetical predisposition for IgAN in children with CN.
Literature
3.
go back to reference Gale DP, Molyneux K, Wimbury D, Higgins P, Levine AP, Caplin B, et al. Galactosylation of IgA1 Is Associated with Common Variation in C1GALT1. J Am Soc Nephrol. 2017;28(7):2158–66.CrossRefPubMedPubMedCentral Gale DP, Molyneux K, Wimbury D, Higgins P, Levine AP, Caplin B, et al. Galactosylation of IgA1 Is Associated with Common Variation in C1GALT1. J Am Soc Nephrol. 2017;28(7):2158–66.CrossRefPubMedPubMedCentral
4.
go back to reference Shibano T, Takagi N, Maekawa K, Mae H, Hattori M, Takeshima Y, et al. Epidemiological survey and clinical investigation of pediatric IgA nephropathy. Clin Exp Nephrol. 2016;20(1):111–7.CrossRefPubMed Shibano T, Takagi N, Maekawa K, Mae H, Hattori M, Takeshima Y, et al. Epidemiological survey and clinical investigation of pediatric IgA nephropathy. Clin Exp Nephrol. 2016;20(1):111–7.CrossRefPubMed
8.
go back to reference Wang T, Ye F, Meng H, Zhang L, Jin X. Comparison of clinicopathological features between children and adults with IgA nephropathy. Pediatr Nephrol. 2012;27(8):1293–300.CrossRefPubMed Wang T, Ye F, Meng H, Zhang L, Jin X. Comparison of clinicopathological features between children and adults with IgA nephropathy. Pediatr Nephrol. 2012;27(8):1293–300.CrossRefPubMed
9.
go back to reference Haas M, Rahman MH, Cohn RA, Fathallah-Shaykh S, Ansari A, Bartosh SM. IgA nephropathy in children and adults: comparison of histologic features and clinical outcomes. Nephrol Dial Transplant. 2008;23(8):2537–45.CrossRefPubMed Haas M, Rahman MH, Cohn RA, Fathallah-Shaykh S, Ansari A, Bartosh SM. IgA nephropathy in children and adults: comparison of histologic features and clinical outcomes. Nephrol Dial Transplant. 2008;23(8):2537–45.CrossRefPubMed
11.
go back to reference Shima Y, Nakanishi K, Hama T, Mukaiyama H, Togawa H, Sako M, et al. Spontaneous remission in children with IgA nephropathy. Pediatr Nephrol. 2013;28(1):71–6.CrossRefPubMed Shima Y, Nakanishi K, Hama T, Mukaiyama H, Togawa H, Sako M, et al. Spontaneous remission in children with IgA nephropathy. Pediatr Nephrol. 2013;28(1):71–6.CrossRefPubMed
13.
15.
go back to reference Nash H, Binns GF, Clarkson AR, Beare TH. Concomitant IgA nephropathy and cyclical neutropenia. Aust N Z J Med. 1978;8(2):184–8.CrossRefPubMed Nash H, Binns GF, Clarkson AR, Beare TH. Concomitant IgA nephropathy and cyclical neutropenia. Aust N Z J Med. 1978;8(2):184–8.CrossRefPubMed
16.
go back to reference Matsukura H, Watanabe S, Ito Y, Kanegane H, Miyawaki T, Shinozaki K. Immunoglobulin A nephropathy associated with cyclic neutropenia. Clin Nephrol. 2005;63(6):502–4.CrossRefPubMed Matsukura H, Watanabe S, Ito Y, Kanegane H, Miyawaki T, Shinozaki K. Immunoglobulin A nephropathy associated with cyclic neutropenia. Clin Nephrol. 2005;63(6):502–4.CrossRefPubMed
17.
go back to reference Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2012 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2012;2:139–274. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2012 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2012;2:139–274.
18.
go back to reference Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021;100(4S):S1-S276. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021;100(4S):S1-S276.
19.
go back to reference Coppo R. Corticosteroids in IgA Nephropathy: Lessons from Recent Studies. J Am Soc Nephrol. 2017;28(1):25–33.CrossRefPubMed Coppo R. Corticosteroids in IgA Nephropathy: Lessons from Recent Studies. J Am Soc Nephrol. 2017;28(1):25–33.CrossRefPubMed
20.
go back to reference Coppo R. Treatment of IgA nephropathy in children: a land without KDIGO guidance. Pediatr Nephrol. 2021;36(3):491–6.CrossRefPubMed Coppo R. Treatment of IgA nephropathy in children: a land without KDIGO guidance. Pediatr Nephrol. 2021;36(3):491–6.CrossRefPubMed
21.
go back to reference Barbour SJ, Coppo R, Er L, Russo ML, Liu ZH, Ding J, et al. International IgA Nephropathy Network. Updating the International IgA Nephropathy Prediction Tool for use in children. Kidney Int. 2021;99(6):1439–50.CrossRefPubMed Barbour SJ, Coppo R, Er L, Russo ML, Liu ZH, Ding J, et al. International IgA Nephropathy Network. Updating the International IgA Nephropathy Prediction Tool for use in children. Kidney Int. 2021;99(6):1439–50.CrossRefPubMed
22.
go back to reference Trimarchi H, Barratt J, Cattran DC, Cook HT, Coppo R, Haas M, et al. IgAN Classification Working Group of the International IgA Nephropathy Network and the Renal Pathology Society; Conference Participants. Oxford Classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working Group. Kidney Int. 2017;91(5):1014–21.CrossRefPubMed Trimarchi H, Barratt J, Cattran DC, Cook HT, Coppo R, Haas M, et al. IgAN Classification Working Group of the International IgA Nephropathy Network and the Renal Pathology Society; Conference Participants. Oxford Classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working Group. Kidney Int. 2017;91(5):1014–21.CrossRefPubMed
23.
go back to reference Tigue CC, McKoy JM, Evens AM, Trifilio SM, Tallman MS, Bennett CL. Granulocyte-colony stimulating factor administration to healthy individuals and persons with chronic neutropenia or cancer: an overview of safety considerations from the Research on Adverse Drug Events and Reports project. Bone Marrow Transplant. 2007;40(3):185–92.CrossRefPubMed Tigue CC, McKoy JM, Evens AM, Trifilio SM, Tallman MS, Bennett CL. Granulocyte-colony stimulating factor administration to healthy individuals and persons with chronic neutropenia or cancer: an overview of safety considerations from the Research on Adverse Drug Events and Reports project. Bone Marrow Transplant. 2007;40(3):185–92.CrossRefPubMed
24.
go back to reference Cottle TE, Fier CJ, Donadieu J, Kinsey SE. Risk and benefit of treatment of severe chronic neutropenia with granulocyte colony-stimulating factor. Semin Hematol. 2002;39(2):134–40.CrossRefPubMed Cottle TE, Fier CJ, Donadieu J, Kinsey SE. Risk and benefit of treatment of severe chronic neutropenia with granulocyte colony-stimulating factor. Semin Hematol. 2002;39(2):134–40.CrossRefPubMed
25.
go back to reference Funakoshi Y, Nazneen A, Nakashima Y, Nakashima K, Okada M, Taguchi T, et al. Possible involvement of G-CSF in IgA nephropathy developing in an allogeneic peripheral blood SCT donor. Bone Marrow Transplant. 2010;45(9):1477–8.CrossRefPubMed Funakoshi Y, Nazneen A, Nakashima Y, Nakashima K, Okada M, Taguchi T, et al. Possible involvement of G-CSF in IgA nephropathy developing in an allogeneic peripheral blood SCT donor. Bone Marrow Transplant. 2010;45(9):1477–8.CrossRefPubMed
26.
go back to reference Dagia NM, Gadhoum SZ, Knoblauch CA, Spencer JA, Zamiri P, Lin CP, et al. G-CSF induces E-selectin ligand expression on human myeloid cells. Nat Med. 2006;12(10):1185–90.CrossRefPubMed Dagia NM, Gadhoum SZ, Knoblauch CA, Spencer JA, Zamiri P, Lin CP, et al. G-CSF induces E-selectin ligand expression on human myeloid cells. Nat Med. 2006;12(10):1185–90.CrossRefPubMed
28.
go back to reference Levy M. Familial cases of Berger’s disease and anaphylactoid purpura: more frequent than previously thought. Am J Med. 1989;87(2):246–8.CrossRefPubMed Levy M. Familial cases of Berger’s disease and anaphylactoid purpura: more frequent than previously thought. Am J Med. 1989;87(2):246–8.CrossRefPubMed
29.
go back to reference Julian BA, Quiggins PA, Thompson JS, Woodford SY, Gleason K, Wyatt RJ. Familial IgA nephropathy. Evidence of an inherited mechanism of disease. N Engl J Med. 1985;312(4):202–8.CrossRefPubMed Julian BA, Quiggins PA, Thompson JS, Woodford SY, Gleason K, Wyatt RJ. Familial IgA nephropathy. Evidence of an inherited mechanism of disease. N Engl J Med. 1985;312(4):202–8.CrossRefPubMed
30.
go back to reference Scolari F, Amoroso A, Savoldi S, Mazzola G, Prati E, Valzorio B, et al. Familial clustering of IgA nephropathy: further evidence in an Italian population. Am J Kidney Dis. 1999;33(5):857–65.CrossRefPubMed Scolari F, Amoroso A, Savoldi S, Mazzola G, Prati E, Valzorio B, et al. Familial clustering of IgA nephropathy: further evidence in an Italian population. Am J Kidney Dis. 1999;33(5):857–65.CrossRefPubMed
31.
go back to reference Paterson AD, Liu XQ, Wang K, Magistroni R, Song X, Kappel J, et al. Genome-wide linkage scan of a large family with IgA nephropathy localizes a novel susceptibility locus to chromosome 2q36. J Am Soc Nephrol. 2007;18(8):2408–15.CrossRefPubMed Paterson AD, Liu XQ, Wang K, Magistroni R, Song X, Kappel J, et al. Genome-wide linkage scan of a large family with IgA nephropathy localizes a novel susceptibility locus to chromosome 2q36. J Am Soc Nephrol. 2007;18(8):2408–15.CrossRefPubMed
32.
go back to reference Karnib HH, Sanna-Cherchi S, Zalloua PA, Medawar W, D’Agati VD, Lifton RP, Badr K, Gharavi AG. Characterization of a large Lebanese family segregating IgA nephropathy. Nephrol Dial Transplant. 2007;22(3):772–7.CrossRefPubMed Karnib HH, Sanna-Cherchi S, Zalloua PA, Medawar W, D’Agati VD, Lifton RP, Badr K, Gharavi AG. Characterization of a large Lebanese family segregating IgA nephropathy. Nephrol Dial Transplant. 2007;22(3):772–7.CrossRefPubMed
33.
go back to reference Takei T, Hiraoka M, Nitta K, Uchida K, Deushi M, Yu T, et al. Functional impact of IgA nephropathy-associated selectin gene haplotype on leukocyte-endothelial interaction. Immunogenetics. 2006;58(5–6):355–61.CrossRefPubMed Takei T, Hiraoka M, Nitta K, Uchida K, Deushi M, Yu T, et al. Functional impact of IgA nephropathy-associated selectin gene haplotype on leukocyte-endothelial interaction. Immunogenetics. 2006;58(5–6):355–61.CrossRefPubMed
34.
go back to reference Takei T, Iida A, Nitta K, Tanaka T, Ohnishi Y, Yamada R, et al. Association between single-nucleotide polymorphisms in selectin genes and immunoglobulin A nephropathy. Am J Hum Genet. 2002;70(3):781–6.CrossRefPubMedPubMedCentral Takei T, Iida A, Nitta K, Tanaka T, Ohnishi Y, Yamada R, et al. Association between single-nucleotide polymorphisms in selectin genes and immunoglobulin A nephropathy. Am J Hum Genet. 2002;70(3):781–6.CrossRefPubMedPubMedCentral
35.
go back to reference Chawla LS, Bellomo R, Bihorac A, Goldstein SL, Siew ED, Bagshaw SM. Acute Disease Quality Initiative Workgroup 16. Acute kidney disease and renal recovery: consensus report of the Acute Disease Quality Initiative (ADQI) 16 Workgroup. Nat Rev Nephrol. 2017;13(4):241–57.CrossRefPubMed Chawla LS, Bellomo R, Bihorac A, Goldstein SL, Siew ED, Bagshaw SM. Acute Disease Quality Initiative Workgroup 16. Acute kidney disease and renal recovery: consensus report of the Acute Disease Quality Initiative (ADQI) 16 Workgroup. Nat Rev Nephrol. 2017;13(4):241–57.CrossRefPubMed
36.
go back to reference Rajasekaran A, Julian BA, Rizk DV. IgA Nephropathy: An Interesting Autoimmune Kidney Disease. Am J Med Sci. 2021;361(2):176–94.CrossRefPubMed Rajasekaran A, Julian BA, Rizk DV. IgA Nephropathy: An Interesting Autoimmune Kidney Disease. Am J Med Sci. 2021;361(2):176–94.CrossRefPubMed
37.
go back to reference Gutiérrez E, Carvaca-Fontán F, Luzardo L, Morales E, Alonso M, Praga M. A Personalized Update on IgA Nephropathy: A New Vision and New Future Challenges. Nephron. 2020;144(11):555–71.CrossRefPubMed Gutiérrez E, Carvaca-Fontán F, Luzardo L, Morales E, Alonso M, Praga M. A Personalized Update on IgA Nephropathy: A New Vision and New Future Challenges. Nephron. 2020;144(11):555–71.CrossRefPubMed
Metadata
Title
Cyclic neutropenia and concomitant IgA nephropathy: a case report
Authors
C. Kapogiannis
T. Zaggogianni
N. Stergiou
K. Kakleas
A. Kapogiannis
H. Gakiopoulou
C. Kanaka-Gantenbein
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Nephrology / Issue 1/2023
Electronic ISSN: 1471-2369
DOI
https://doi.org/10.1186/s12882-023-03179-1

Other articles of this Issue 1/2023

BMC Nephrology 1/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine